OVERALL SURVIVAL

AstraZeneca's breast cancer drug combination fails in late-stage trial

Triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known actionable biomarker targets, and chemotherapy-based regimens continue to be the mainstay of treatment, AstraZeneca said.